Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30051
Title: Prevalence, severity, duration and resolution of cholestasis after acute liver failure.
Austin Authors: Warming, Scott;Michel, Claire;Serpa Neto, Ary ;Kishore, Kartik ;Marhoon, Nada ;Holmes, Natasha E ;Bellomo, Rinaldo ;Testro, Adam G ;Sinclair, Marie ;Gow, Paul J ;Warrillow, Stephen J 
Affiliation: Intensive Care
Data Analytics Research and Evaluation (DARE) Centre
Gastroenterology and Hepatology
Australian and New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, Monash University, Clayton, Victoria, Australia..
The University of Melbourne, Melbourne, Victoria, Australia..
Department of Critical Care, The University of Melbourne, Melbourne, Victoria, Australia..
Department of Intensive Care, Albert Einstein Medical Center, Sao Paolo, Brazil..
Department of Intensive Care, Royal Melbourne Hospital, Melbourne, Victoria, Australia..
Issue Date: Apr-2022
Publication information: BMJ Open Gastroenterology 2022; 9(1): e000801
Abstract: Persistent cholestasis may follow acute liver failure (ALF), but its course remains unknown. We aimed to describe the prevalence, onset, severity, duration and resolution of post-ALF cholestasis. Cohort of 127 adult patients with ALF at a liver transplantation centre identified using electronic databases. We obtained laboratory data every 6 hours for the first week, daily until day 30 and weekly, when documented, until day 180. Median age was 40.7 (IQR 31.0-52.4) years, median peak alanine aminotransferase level was 5494 (2521-8819) U/L and 87 (68.5%) cases had paracetamol toxicity. Overall, 12.6% underwent transplantation (3.4% for paracetamol vs 32.5% for non-paracetamol; p<0.001). Ninety-day mortality was 20.7% for paracetamol versus 30.0% for non-paracetamol patients. All non-transplanted survivors reached a bilirubin level>50 µmol/L, which peaked 3.5 (1.0-10.1) days after admission at 169.0 (80.0-302.0) µmol/L. At hospital discharge, 18.8% of patients had normal bilirubin levels and, at a median follow-up time from admission to last measurement of 16 (10-30) days, 46.9% had normal levels. Similarly, there was an increase in alkaline phosphatase (ALP) (207.0 (148.0-292.5) U/L) and gamma-glutamyl transferase (GGT) (336.0 (209.5-554.5) U/L) peaking at 4.5 days, with normalised values in 40.3% and 8.3% at hospital discharge. Post-ALF cholestasis is ubiquitous. Bilirubin, ALP and GGT peak at 3 to 5 days and, return to baseline in the minority of patients at median follow-up of 16 days. These data inform clinical expectations of the natural course of this condition.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30051
DOI: 10.1136/bmjgast-2021-000801
ORCID: 0000-0001-9113-8598
0000-0002-1650-8939
0000-0003-1520-9387
0000-0001-8501-4054
0000-0001-6505-7233
0000-0002-6254-6063
0000-0002-7240-4106
Journal: BMJ Open Gastroenterology
PubMed URL: 35473828
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35473828/
ISSN: 2054-4774
Type: Journal Article
Subjects: acute liver failure
alkaline phosphatase
bilirubin
cholestasis
Appears in Collections:Journal articles

Show full item record

Page view(s)

72
checked on Jul 15, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.